Loading...
Loading...
Canaccord Genuity maintains its Buy rating on DexCom
DXCM and raises its price target to $11.50, up half a dollar, on solid Q4 and a 2012 guidance that is likely conservative.
Canaccord Genuity says, "We reiterate our BUY rating following strong Q4/11 revenue results (in-line with preliminary numbers). Revenue guidance was reaffirmed, but we believe it is conservative. Lastly, the completion (and hopeful submission) of the Gen4 IDE trial during the Q1/12 is encouraging as a new product cycle is needed to drive
major growth and improve profitability in 2013 and beyond."
DXCM closed at $11.19 a share on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in